Crystal Entecavir Formulation Stability and Direct Compression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations for treating chronic hepatitis B virus infection, such as those using Lamivudine and Adefovir, face challenges in stability and production complexity, particularly under conditions of high temperature and humidity, and the boiling granulating process used for entecavir formulations is difficult to control for quality and energy efficiency.
Innovation Solution
A pharmaceutical composition comprising crystal entecavir as the active ingredient, mixed with glidants, diluents, adhesives, and disintegrants, and formulated into tablets or capsules through a simpler direct tabletting or filling process, which is more suitable for industrial production and reduces energy consumption and production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If boiling granulating process is used for entecavir formulation, then uniform distribution of active ingredients is ensured, but process complexity and difficulty of quality control increase
Solution Approach 1:
The patent extracts and eliminates the boiling granulating step from the formulation process. By using direct compression or simple mixing methods instead of boiling granulation, the process complexity is reduced while maintaining uniform distribution of active ingredients through proper mixing techniques and formulation design.
Solution Approach 2:
The patent changes the processing parameters from high-temperature boiling granulation to room-temperature direct compression or mixing. This parameter change simplifies the process while achieving uniform distribution through optimized mixing time, speed, and formulation composition rather than thermal processing.
2Manufacturing precision
If boiling granulating process is used for entecavir formulation, then product quality can be maintained, but energy consumption increases
Solution Approach 1:
The patent removes the energy-intensive boiling granulating step from the process. By adopting direct compression or simple mixing methods, significant energy consumption is eliminated while product quality is maintained through optimized formulation and mixing protocols that do not require thermal processing.
Solution Approach 2:
The patent replaces the thermal system (boiling granulation requiring heat energy) with a mechanical system (direct compression or mixing). This substitution eliminates the need for continuous heating while achieving uniform product quality through mechanical force and proper formulation design.
3Adaptability or versatility
If amorphous entecavir is used as active ingredient, then formulation flexibility is improved, but stability under high temperature and humidity conditions deteriorates
Solution Approach 1:
The patent changes the physical state parameter of entecavir from amorphous to crystalline form. This parameter change enhances stability under high temperature and humidity conditions while maintaining formulation flexibility through proper selection of excipients and formulation techniques that work effectively with the crystalline structure.
Solution Approach 2:
The patent uses composite material strategies by combining crystalline entecavir with specific excipients that maintain formulation flexibility. The composite formulation approach allows the crystalline form to provide stability while the excipient combination ensures proper flow, compression, and release characteristics.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.